research use only

Glasdegib Hedgehog/Smoothened inhibitor

Cat.No.S7160

Glasdegib is a potent, and orally bioavailable Smoothened (Smo) inhibitor with IC50 of 5 nM. Phase 2.
Jump to

Quality Control

Batch: S716002 DMSO]74 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.49%
99.49

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C3H10T1/2 Function assay 20 hrs Inhibition of Smo in mouse C3H10T1/2 cells using human recombinant SHH assessed as effect on SMO/SHH transient transcriptional activation after 20 hrs by Gli-luciferase reporter assay, IC50=0.005μM 24900436
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 74 mg/mL (197.62 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 374.44 Formula

C21H22N6O

Storage (From the date of receipt)
CAS No. 1095173-27-5 Download SDF Storage of Stock Solutions

Synonyms PF-04449913 SMILES CN1CCC(CC1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
Smoothened
5 nM
In vitro
In vitro microsomal assays, PF-04449913 have high clearance in rat and low clearance in dog and human, without inhibiting any of the major cytochrome P450 isoforms.
In vivo
In rat and dog, PF-04449913 shows high clearance, and good oral bioavailability.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-16)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04231851 ACTIVE_NOT_RECRUITING
Acute Myelogenous Leukemia (AML) Due to Therapy; Acute Myeloid Leukemia With Myelodysplasia-Related Changes
University of California, Irvine
2020-02-19 PHASE2
NCT03226418 COMPLETED
Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia
University of Nebraska
2017-07-07 PHASE2
NCT04655391 WITHDRAWN
Recurrent Acute Myeloid Leukemia
City of Hope Medical Center
2022-06-25 PHASE1
NCT03784014 COMPLETED
Soft Tissue Sarcoma
Institut National de la Santé Et de la Recherche Médicale, France
2019-10-19 PHASE3
NCT03466450 COMPLETED
Glioblastoma
Grupo Español de Investigación en Neurooncología
2018-03-15 PHASE1; PHASE2
NCT04111497 TERMINATED
Chronic Graft Versus Host Disease; Fasciitis
Fred Hutchinson Cancer Center
2019-12-03 PHASE1; PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map